Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31281299 | 1.00 | HMGCR (0.54) | HMGCRKDM4ELMNAHTTMAPK1 | |
| SCHEMBL31421865 | 0.88 | HMGCR (0.46) | HMGCRKDM4E | |
| SCHEMBL25266060 | 0.87 | KDM4E (0.47) | HMGCRKDM4ELMNAHTTMAPK1 | |
| SCHEMBL9559776 | 0.86 | HMGCR (0.66) | HMGCRKDM4ELMNAHTT | |
| SCHEMBL30161227 | 0.86 | HMGCR (0.66) | HMGCRKDM4ELMNAHTT | |
| SCHEMBL29467671 | 0.86 | KDM4E (0.46) | HMGCRKDM4ELMNAHTTMAPK1 | |
| SCHEMBL23929262 | 0.86 | KDM4E (0.46) | HMGCRKDM4ELMNAHTTMAPK1 | |
| SCHEMBL13181120 | 0.83 | ALDH1A1 (0.41) | HMGCRKDM4ELMNAHTTMAPK1 | |
| SCHEMBL25194465 | 0.82 | KDM4E (0.43) | HMGCRKDM4ELMNAHTTMAPK1 | |
| SCHEMBL2310679 | 0.81 | KDM4E (0.51) | KDM4ELMNAHTTMAPK1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023078273-A1 | SPECIFIC CONJUGATION FOR AN ANTIBODY-DRUG CONJUGATE | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-05-11 | — | — | WO | disclosed |
| WO-2022078524-A2 | SPECIFIC CONJUGATION OF AN ANTIBODY | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2022-04-21 | — | — | WO | disclosed |
| WO-2021212638-A1 | CONJUGATES OF A CELL-BINDING MOLECULE WITH CAMPTOTHECIN ANALOGS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2021-10-28 | — | — | WO | disclosed |
| US-7135478-B2 | Analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them | SOCIETE DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2006-11-14 | — | — | US | disclosed |
| US-7053102-B2 | Analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them | SOCIETE DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2006-05-30 | — | — | US | disclosed |
| EP-1251125-B1 | New camptothecin analogues, preparation methods thereof, use thereof as drugs, and pharmaceutical compositions containing them | SOD CONSEILS RECH APPLIC (FR) | 2005-12-07 | — | — | EP | disclosed |
| US-20050038064-A1 | Anticarcinogenic agents; breast, colon, lung, prostate, ovarian, and gastric cancers, leukemia, melanomas; (5R)-5-ethyl-9,10-difluoro-5-hydroxy-4,5,13,15-tetrahydro-1H,3H-oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione | SOCIETE DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) | 2005-02-17 | — | — | US | disclosed |
| US-20040254163-A1 | New analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them | SOCIETE DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) | 2004-12-16 | — | — | US | disclosed |
| US-6815546-B2 | ANTICANCER AGENTS | SOCIETE DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-11-09 | — | — | US | disclosed |
| US-6797715-B1 | Analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-09-28 | — | — | US | disclosed |
| US-5981542-A | TOPOISOMERASE INHIBITORS; ANTITUMORAL DRUGS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 1999-11-09 | — | — | US | disclosed |
| EP-0946567-A1 | NOVEL COUNTERPARTS OF CAMPTOTHECIN, THEIR APPLICATION AS MEDICINE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 1999-10-06 | — | — | EP | disclosed |
| EP-0946566-A1 | PRO-DRUGS AND COUNTERPARTS OF CAMPTOTHECIN, THEIR APPLICATION AS MEDICINES | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998028304-A1 | PRO-DRUGS AND COUNTERPARTS OF CAMPTOTHECIN, THEIR APPLICATION AS MEDICINES | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 1998-07-02 | — | — | WO | disclosed |
| WO-1998028305-A1 | NOVEL COUNTERPARTS OF CAMPTOTHECIN, THEIR APPLICATION AS MEDICINE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 1998-07-02 | — | — | WO | disclosed |
| EP-0835258-A1 | NOVEL CAMPTOTHECIN ANALOGUES, PREPARATION METHODS THEREFOR, USE THEREOF AS DRUGS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID ANALOGUES | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 1998-04-15 | — | — | EP | disclosed |
| WO-1997000876-A1 | NOVEL CAMPTOTHECIN ANALOGUES, PREPARATION METHODS THEREFOR, USE THEREOF AS DRUGS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID ANALOGUES | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (SCRAS) (FR) | 1997-01-09 | — | — | WO | disclosed |
| EP-0325247-B1 | CAMPTOTHECIN DERIVATIVES AND PROCESS FOR PREPARING SAME | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 1993-05-19 | — | — | EP | disclosed |
| US-5061800-A | ANTITUMOR AGENTS | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 1991-10-29 | — | — | US | disclosed |
| EP-0325247-A1 | Camptothecin derivatives and process for preparing same | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 1989-07-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254163-A1 | New analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them | TOP2A, TOP1, MCL1 | HMGCR 100/4885KDM4E 4381/4885LMNA 857/4885 |
| US-20050038064-A1 | Anticarcinogenic agents; breast, colon, lung, prostate, ovarian, and gastric cancers, leukemia, melanomas; (5R)-5-ethyl-9,10-difluoro-5-hydroxy-4,5,13,15-tetrahydro-1H,3H-oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione | MCL1, BRCA1, API5 | HMGCR 1775/4885KDM4E 699/4885LMNA 2019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.